Monopar Therapeutics (NASDAQ:MNPR) Releases Earnings Results, Misses Estimates By $0.10 EPS

Monopar Therapeutics (NASDAQ:MNPR) released its quarterly earnings data on Friday. The company reported ($0.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.10), FiscalAI reports.

Monopar Therapeutics Price Performance

Monopar Therapeutics stock opened at $54.10 on Friday. Monopar Therapeutics has a fifty-two week low of $26.06 and a fifty-two week high of $105.00. The firm has a fifty day moving average price of $59.62 and a two-hundred day moving average price of $70.75. The firm has a market cap of $361.39 million, a price-to-earnings ratio of -29.73 and a beta of 1.58.

Hedge Funds Weigh In On Monopar Therapeutics

A number of institutional investors have recently made changes to their positions in the business. Russell Investments Group Ltd. acquired a new stake in shares of Monopar Therapeutics during the 3rd quarter worth approximately $28,000. BNP Paribas Financial Markets raised its stake in shares of Monopar Therapeutics by 100.6% in the third quarter. BNP Paribas Financial Markets now owns 696 shares of the company’s stock valued at $57,000 after purchasing an additional 349 shares in the last quarter. Meeder Asset Management Inc. bought a new position in Monopar Therapeutics in the fourth quarter worth $65,000. JPMorgan Chase & Co. lifted its position in Monopar Therapeutics by 1,821.0% in the second quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company’s stock worth $69,000 after purchasing an additional 1,821 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in Monopar Therapeutics during the second quarter worth $80,000. 1.83% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts have commented on MNPR shares. Morgan Stanley assumed coverage on shares of Monopar Therapeutics in a research report on Friday, January 9th. They set an “overweight” rating and a $115.00 target price on the stock. Wall Street Zen downgraded Monopar Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, January 10th. Cantor Fitzgerald reissued an “overweight” rating on shares of Monopar Therapeutics in a report on Wednesday, January 21st. Chardan Capital reissued a “buy” rating and issued a $100.00 price objective on shares of Monopar Therapeutics in a research note on Thursday, January 29th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Monopar Therapeutics in a report on Thursday, January 22nd. Two investment analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Monopar Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $107.00.

Monopar Therapeutics Company Profile

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.